Manufacturers

Neuronix

118, Washington Street , 01746 Holliston
USA

Telephone +1 508 2833200
ggregory@neuronixmedical.com

This company is co-exhibitor of
Israel Export & International Cooperation Institute

Trade fair hall

  • Hall 16 / G40
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 16): stand G40

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.10  Stimulation equipment for diagnostics / therapy

Stimulation equipment for diagnostics / therapy

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.10  Stimulation equipment for diagnostics / therapy
  • 01.03.10.01  Pressure distribution measuring instruments

Pressure distribution measuring instruments

Our products

Product category: Stimulation equipment for diagnostics / therapy

neuroAD Therapy System

neuroAD is a novel, non-invasive medical device which has helped many Alzheimer’s Disease patients achieve sustained cognitive improvement. This treatment is typically combined with Alzheimer’s Disease medication, and offers new hope for patients to enjoy better quality of life.

More Less

About us

Company details

Established in 2008, Neuronix develops new methods for modifying the course of treatment for Alzheimer’s Disease (AD) and offers hope and the potential for long-term improvement in the quality of life of patients. Led by a highly motivated management team and supported by an Advisory Board of key opinion leaders in the field, Neuronix’s neuroAD solution is currently undergoing a multi-site clinical study in the United States and is commercially available in clinics in Europe and Israel.

Restore cognitive function in mild to moderate Alzheimer’s Disease

The neuroAD system is based on the company’s core Non Invasive Cortical Enhancer (NICE™) technology and CE-marked for the treatment of mild to moderate Alzheimer’s Disease. This patented technology uses Magnetic Stimulation, concurrently interlaced with Cognitive Training and directed at specific brain regions affected by Alzheimer’s Disease. This combination induces LTP (Long-Term Potentiation), which is associated with learning and memory processes. Results have indicated measurable cognitive improvement, after just a few weeks of treatment, which has shown to last for up to one year.

Peer-reviewed clinical data

Clinical trials performed at the Harvard Medical School and in Israel, showed statistically significant clinical results compared with placebo. neuroAD is CE-marked for commercial use in Europe for the treatment of Alzheimer patients. neuroAD is currently undergoing a multi-center study in the U.S. for FDA approval.

Neuronix is a privately-held company with headquarters in Israel.

More Less

Company data

Sales volume

< 1 Mio US $

Number of employees

20-49

Foundation

2008

Area of business

Electromedical equipment / Medical Technology